Keeb kwm
Incretin-raws li kev kho mob tau ntev tau paub los txhim kho ob qho tib sitswj ntshav qabzibthiablub cev hnyav txo. Traditional incretin tshuaj feem ntau tsom rauGLP-1 receptor, thaumTirzepatidesawv cev rau tiam tshiab ntawm "ntxaibcretin"tus neeg sawv cev - ua haujlwm rauob qho tib si GIP (glucose-dependent insulinotropic polypeptide)thiabGLP-1cov receptors.
Qhov kev ua ob zaug no tau pom los txhim kho cov txiaj ntsig metabolic thiab txhawb kev poob phaus ntau dua piv rau GLP-1 agonists ib leeg.
SURMOUNT-1 Kawm Tsim
TSEEM CEEB-1ua arandomized, ob-dig muag, theem 3 soj ntsuam kuajtau ua thoob 119 qhov chaw hauv cuaj lub tebchaws.
Cov neeg koom nrog suav nrog cov neeg laus uas yog:
- Kev rog(BMI ≥ 30), lossis
- Poob hnyav(BMI ≥ 27) nrog tsawg kawg ib qho kev hnyav hnyav (piv txwv li, kub siab, dyslipidemia, pw tsaug zog apnea, lossis kab mob plawv).
Cov neeg muaj ntshav qab zib, kev siv tshuaj poob phaus tsis ntev los no, lossis kev phais bariatric ua ntej raug cais tawm.
Cov neeg koom nrog raug muab tso rau kom tau txais kev txhaj tshuaj ib zaug ib lub lim tiam ntawm:
- Tirzepatide 5 mg, 10 mg, 15 mg ib, los yog
- Cov tshuaj placebo
Txhua tus neeg tuaj koom kuj tau txais kev qhia txog kev ua neej nyob:
- A caloric tsis txaus ntawm 500 kcal / hnub
- Tsawg kawg150 feeb ntawm lub cev ua si ib lub lim tiam
Kev kho mob tau ntev72 lis, suav a20-lub lim tiam koob tshuaj-escalation theemua raws li 52 lub lis piam txij nkawm.
Cov ntsiab lus tshwm sim
Tag nrho ntawm2,359 tus neeg koomtau cuv npe.
Qhov nruab nrab hnub nyoog yog44,9 xya, 67.5% yog poj niam, nrog lub ntsiab luslub cev hnyav 104.8 kgthiabBMI ntawm 38.0.
Lub cev hnyav txo ntawm lub lis piam 72
| Dose Group | % Qhov hnyav hloov | Qhov ntsuas qhov hnyav (kg) | Ntxiv Loss vs Placebo |
|---|---|---|---|
| 5mg ib | -15.0% | - 16.1 kg | -13.5% |
| 10 mg | -19.5% | - 22.2 kg | -18.9% |
| 15 mg ib | -20.9% | - 23.6 kg | -20.1% |
| Cov tshuaj placebo | -3.1% | - 2.4 kg | — |
Tirzepatide ua tiav 15-21% txhais tau tias lub cev hnyav txo, ua kom pom tseeb cov teebmeem ntawm koob tshuaj.
Qhov feem pua ntawm cov neeg koom ua tiav qhov kev poob phaus
| Poob poob (%) | 5mg ib | 10 mg | 15 mg ib | Cov tshuaj placebo |
|---|---|---|---|---|
| ≥5% | 85.1% | 88.9% | 90.9% | 34.5% |
| ≥10% | 68.5% | 78.1% | 83.5% | 18.8% |
| ≥15% | 48.0% | 66.6% | 70.6% | 8.8% |
| ≥20% | 30.0% | 50.1% | 56.7% | 3.1% |
| ≥25% | 15.3% | 32.3% | 36.2% | 1.5% |
Ntau tshaj ib nrabntawm cov neeg koom tau txais≥ 10 mgTirzepatide ua tiav≥20% poob phaus, mus txog qhov tshwm sim pom nrog kev phais bariatric.
Cov txiaj ntsig metabolic thiab mob plawv
Piv nrog rau cov placebo, Tirzepatide zoo dua:
- Lub duav ncig
- Systolic ntshav siab
- Lipid profile
- Kev yoo mov qib insulin
Ntawm cov neeg koom nrogntshav qab zib, 95.3% rov qab mus rau qib qabzib qub, piv rau61.9%hauv pawg placebo - qhia Tirzepatide tsis yog tsuas yog pab txo qhov hnyav xwb tab sis kuj txhim kho cov piam thaj metabolism.
Kev nyab xeeb thiab kam rau ua
Cov kev mob tshwm sim feem ntau yogplab hnyuv, suav nrogxeev siab, raws plab, thiab cem quav, feem ntau me me thiab ib ntus.
Tus nqi txiav tawm vim qhov tshwm sim tsis zoo yog kwv yees li4-7%.
Qee qhov kev tuag tshwm sim thaum lub sijhawm sim, feem ntau txuas nrogCOVID 19, thiab tsis cuam tshuam ncaj qha rau txoj kev tshawb fawb tshuaj.
Tsis muaj qhov sib txawv tseem ceeb tau pom nyob rau hauv cov teeb meem ntsig txog gallbladder.
Kev sib tham
Kev hloov pauv kev ua neej nyob ib leeg (kev noj haus thiab kev tawm dag zog) feem ntau tsuas yog ua tau~ 3% qhov hnyav nruab nrab, raws li pom hauv pawg placebo.
Hauv qhov sib piv, Tirzepatide enabled15-21% tag nrho lub cev hnyav txo, sawv cev a5-7 npaug ntau dua cov nyhuv.
Piv nrog:
- Qhov ncauj yuag-lossis tshuaj:feem ntau ua tiav 5-10% poob
- Bariatric phais:ua tiav> 20% poob
Tirzepatide txuas qhov sib txawv ntawm cov tshuaj pharmacological thiab kev phais mob - muabhaib, tsis-invasive hnyav txo.
Qhov tseem ceeb, kev txhawj xeeb txog kev ua kom cov piam thaj metabolism tsis zoo tsis tau pom. Ntawm qhov tsis sib xws, Tirzepatide txhim kho insulin rhiab heev thiab thim rov qab prediabetes hauv feem ntau cov neeg koom.
Txawm li cas los xij, qhov kev sim no piv Tirzepatide nrog cov placebo - tsis ncaj qha nrogSemaglutide.
Kev sib piv ntawm lub taub hau yog xav tau los txiav txim seb tus neeg sawv cev twg ua rau poob phaus ntau dua.
Xaus
Rau cov neeg laus uas muaj rog lossis rog dhau thiab muaj feem cuam tshuam, ntxivTirzepatide ib zaug ib lub lim tiammus rau qhov kev pab cuam txoj kev ua neej (kev noj haus + kev tawm dag zog) tuaj yeem ua rau:
- 15-21% nruab nrab lub cev hnyav txo
- Kev txhim kho metabolic tseem ceeb
- Siab kam rau ua thiab kev nyab xeeb
Tirzepatide yog li sawv cev rau kev kho kom zoo thiab kho tau zoo rau kev noj qab haus huv, kev tswj xyuas qhov hnyav.
Post lub sij hawm: Oct-16-2025